Tscan Therapeutics Inc
NASDAQ:TCRX 11:49:12 AM EDT
| Market Cap (Intraday) | 84.03M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.50 |
| 50-Day MA | $1.50 |
| 200-Day MA | $2.92 |
Tscan Therapeutics Inc Stock, NASDAQ:TCRX
830 Winter Street, Waltham, Massachusetts 02451
United States of America
Phone: +1.857.399.9500
Number of Employees: 194
Description
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.